Real World Data for the Treatment of Chronic Hepatitis C genotype 1 in an Academic Center Based Practice.
AAPA ePoster library. Mayberry J. 05/17/17; 180539; 201
Jordan Mayberry
Jordan Mayberry
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
TITLE: Real World Data for the Treatment of Chronic Hepatitis C genotype 1 in an Academic Center Based Practice. PURPOSE: Ledipasivir- sofosbuvir (LDV/SOF) ± ribavirin was approved for treatment of chronic hepatitis C genotype 1 and 4. Sustained Virologic Response (SVR) rates in clinical trials are ≥ 95% in many treatment types. SVR12 is defined as an undetected viral load 12 weeks after completing therapy. SVR12 is considered a cure of chronic hepatitis C. The purpose of this data review is to compare UTSW SVR rates to the national average rates to determine if changes in the UTSW clinical protocol are necessary. Methods: This retrospective chart review covered dates 10/2014 to 12/2016. Charts reviewed consisted of patients treated at UTSW Digestive and Liver Disease outpatient clinic. Variables were selected based on the national guidelines for SVR rates. Variables reviewed included patient age, sex, hepatic fibrosis score, previous treatment for hepatitis C, co-morbidities and if patient reached SVR12. Patients were treated with LDV/SOF for 8, 12 vs 24 weeks. Regimen and duration was chosen by the health care provider based on baseline factors. Results: A total of 347 patients were treated, 10 patients were not placed on Sofosbuvir based therapy, 28 patients were lost to follow-up and 4 relapsed following treatment: When compared to clinical trial SVR12 rates our patient population had a lower SVR12 rate at 90%. Patients lost to follow-up at 8%. The percentage of patients that relapsed following treatment was 1%. This is the initial analysis upon acceptance plan to further analyze SVR12 rates based on fibrosis score, treatment duration and genotype. Conclusion: After accounting for lost to follow-up SVR12 rates are similar for UT Southwestern and the national averages. The Sofosbuvir based treatment regimens were associated with an SVR12 rate of 90%. The improvement in patient follow-up is vital to clinical practice because, patients that reached SVR12 are shown to have decreased complication rates from liver disease....
TITLE: Real World Data for the Treatment of Chronic Hepatitis C genotype 1 in an Academic Center Based Practice. PURPOSE: Ledipasivir- sofosbuvir (LDV/SOF) ± ribavirin was approved for treatment of chronic hepatitis C genotype 1 and 4. Sustained Virologic Response (SVR) rates in clinical trials are ≥ 95% in many treatment types. SVR12 is defined as an undetected viral load 12 weeks after completing therapy. SVR12 is considered a cure of chronic hepatitis C. The purpose of this data review is to compare UTSW SVR rates to the national average rates to determine if changes in the UTSW clinical protocol are necessary. Methods: This retrospective chart review covered dates 10/2014 to 12/2016. Charts reviewed consisted of patients treated at UTSW Digestive and Liver Disease outpatient clinic. Variables were selected based on the national guidelines for SVR rates. Variables reviewed included patient age, sex, hepatic fibrosis score, previous treatment for hepatitis C, co-morbidities and if patient reached SVR12. Patients were treated with LDV/SOF for 8, 12 vs 24 weeks. Regimen and duration was chosen by the health care provider based on baseline factors. Results: A total of 347 patients were treated, 10 patients were not placed on Sofosbuvir based therapy, 28 patients were lost to follow-up and 4 relapsed following treatment: When compared to clinical trial SVR12 rates our patient population had a lower SVR12 rate at 90%. Patients lost to follow-up at 8%. The percentage of patients that relapsed following treatment was 1%. This is the initial analysis upon acceptance plan to further analyze SVR12 rates based on fibrosis score, treatment duration and genotype. Conclusion: After accounting for lost to follow-up SVR12 rates are similar for UT Southwestern and the national averages. The Sofosbuvir based treatment regimens were associated with an SVR12 rate of 90%. The improvement in patient follow-up is vital to clinical practice because, patients that reached SVR12 are shown to have decreased complication rates from liver disease....
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings